CATALYST PHARMACEUTICALS, INC. - COMMON STOCK (CPRX)

Q4 2017 13F Holders as of 31 Dec 2017

Type / Class
Equity / COMMON STOCK
Shares outstanding
123,180,519
Total 13F shares
56,055,280
Share change
+20,114,662
Total reported value
$219,183,091
Put/Call ratio
100%
Price per share
$3.91
Number of holders
105
Value change
+$80,363,139
Number of buys
63
Number of sells
32

Institutional Holders of CATALYST PHARMACEUTICALS, INC. - COMMON STOCK (CPRX) as of Q4 2017

As of 31 Dec 2017, CATALYST PHARMACEUTICALS, INC. - COMMON STOCK (CPRX) was held by 105 institutional shareholders that filed Form 13F with the SEC. Together, they reported ownership of 56,055,280 shares. The largest 10 holders included Broadfin Capital, LLC, BAKER BROS. ADVISORS LP, Consonance Capital Management LP, BlackRock Inc., venBio Select Advisor LLC, GREAT POINT PARTNERS LLC, Vanguard Group Inc, MILLENNIUM MANAGEMENT LLC, JPMORGAN CHASE & CO, and EMERALD ADVISERS INC/PA. This page lists 105 institutional shareholders reporting positions in this security for the Q4 2017 filing period.
Investor Option Weight % Change % Value $ * Price Shares Share Change Activity Report Period
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.